ClinicalTrials.gg
RecruitingNCT06846281Updated Oct 26, 2026

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

A Phase 3 interventional study of Remibrutinib oral treatment and Ocrelizumab in Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Recruiting at 131 sites in 19 countries. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Oct 26, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Multiple Sclerosis by Novartis — 9 open to participants now, 24 under way, 6 of them phase 3. Multiple Sclerosis · Novartis.

Planned enrollment
15th of 64
400 · median 147
Started
2025
with 4 others
Phase 3
23 of 106
2 open now
Primary completion
2029-07
later than 18 of 23 live
Registered
98th of 106
by date

Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 15th largest by planned enrollment of the 64 interventional ones that give a count, is one of 5 that started in 2025, is one of 23 in phase 3, reaches primary completion later than 18 of the 23 other live ones, and was the 98th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

9 of the 106 studies in Multiple Sclerosis by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Multiple Sclerosis by Novartis, or all of them as a file.
02

Study summary

The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

Read the detailed description

The study is a randomized, open-label, non-inferiority multi-center, Phase 3b study to provide efficacy, safety, and tolerability data for remibrutinib after switching from ocrelizumab and in comparison to continuous ocrelizumab in plwRMS.

This study consists of an initial Core Part (CP) (maximum duration per participant of up to 24 months), followed by an Extension Part (EP) (of up to 24 months duration) for eligible participants.

All participants completing the 24-month treatment of the Core Part of the study may be eligible to continue in the Extension Part, an open-label, single-arm, fixed-dose design in which participants are treated with remibrutinib for up to 24 months.

The study will be conducted in the USA among other countries globally.

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • MS
  • RMS
  • Remibrutinib
  • LOU064
  • Ocrelizumab
  • Age
  • MRI
  • T2 lesions
  • NEDA-3
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female aged 40 to 70 years (inclusive)
  • Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
  • Treated with ocrelizumab according to routine clinical practice and at standard dose
  • Neurologically stable within 30 days
  • Suitable to be switched to remibrutinib based on physician judgement or patient preference

Key Exclusion Criteria:

  • Diagnosis of primary progressive multiple sclerosis (PPMS) according to the revised 2017 McDonald criteria
  • History of Central Nervous System disease or neurological disorders
  • History of confirmed Progressive Multifocal Leukoencephalopathy or neurological symptoms consistent
  • Active clinically significant systemic bacterial, viral, parasitic or fungal infections
  • Active, chronic disease of the immune system other than MS
  • Severe cardiac disease or significant findings on the
  • Participant who is unable to undergo MRI scans
  • History of life-threatening infusion or injection reaction related to ocrelizumab
  • Participants not adequately controlled on ocrelizumab (CD19+ B-cell count ≥10 cells/µL at screening)

Other inclusion and exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Remibrutinib Core

    Remibrutinib tablet taken orally

    Drug: Remibrutinib oral treatment

  • Active comparator
    Ocrelizumab Core

    Ocrelizumab at standard dose and route of administration (i.v. or s.c) per label

    Drug: Ocrelizumab

  • Experimental
    Remibrutinib Extension

    Remibrutinib tablet taken orally

    Drug: Remibrutinib oral treatment

  • Experimental
    Remibrutinib Extension (Ocrelizumab in Core)

    Remibrutinib tablet taken orally

    Drug: Remibrutinib oral treatment

Interventions

06

What researchers measure

Primary outcomes

  1. Annualized rate of new or enlarging T2 lesions_Core Part

    Number of new/enlarging T2 lesions per year on MRI at month 24 (relative to baseline)

    Time frame: Baseline up to month 24

Secondary outcomes

  1. Participants with no evidence of disease activity-3 (NEDA-3)_Core Part

    Participants with no evidence of disease activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6-month confirmed disability progression (6mCDP) and new/enlarging T2 lesions on MRI

    Time frame: Baseline up to month 24

  2. Number of adverse events (AEs) and serious adverse events (SAEs)_Core Part

    Adverse events will be collected throughout the trial. Any safety assessment findings such as laboratory, vital signs, electrocardiogram data that are considered clinically significant or meet the protocol definition of an adverse event will be reported as adverse event or serious adverse event, as appropriate

    Time frame: Baseline up to month 24

  3. Annualized rate of new or enlarging T2 lesions_Extension Part

    Number of new/enlarging T2 lesions per year on MRI

    Time frame: Month 24 up to month 48

  4. Participants with no evidence of disease activity-3 (NEDA-3)_Extension Part

    Participants with no evidence of disease activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6-month confirmed disability progression (6mCDP) and new/enlarging T2 lesions on MRI

    Time frame: Month 24 up to month 48

  5. Number of Adverse events and serious adverse events_Extension Part

    Adverse events will be collected throughout the trial. Any safety assessment findings such as laboratory, vital signs, electrocardiogram data that are considered clinically significant or meet the protocol definition of an adverse event will be reported as adverse event or serious adverse event, as appropriate

    Time frame: Month 24 up to month 48

07

Study locations

128 of 131 sites recruiting
  • Perseverance Research Center
    Scottsdale, Arizona 85253, United States
    Recruiting
  • University of California Irvine
    Irvine, California 92697, United States
    Recruiting
    • Veronica Martin · Contactvero@hs.uci.edu
    • Michael Sy · Principal investigator
  • Medstar Washington Hospital Center
    Washington D.C., District of Columbia 20010-2975, United States
    Recruiting
  • Neurology of Central FL Res Ctr
    Altamonte Springs, Florida 32714, United States
    Recruiting
  • University of Florida
    Gainesville, Florida 32610, United States
    Recruiting
    • Whitney Miller · Contactwjm1433@ufl.edu
    • Torge Rempe · Principal investigator
  • Memorial Healthcare System
    Hollywood, Florida 33021, United States
    Recruiting
    • Hina Khan · Contacthikhan@mhs.net · +1 954 265 6934
    • Buse Sengul · Principal investigator
  • Neurology Associates PA
    Maitland, Florida 32751, United States
    Recruiting
  • Elite Clinical Research
    Miami, Florida 33144, United States
    Recruiting
  • Aqualane Clinical Research
    Naples, Florida 34105, United States
    Recruiting
  • Advent Health Orlando
    Orlando, Florida 32803, United States
    Recruiting
  • Orlando Health Clinical Trials
    Orlando, Florida 32806, United States
    Recruiting
  • Tallahassee Neurological Clinic
    Tallahassee, Florida 32308, United States
    Recruiting
  • University Of South Florida
    Tampa, Florida 33612, United States
    Recruiting
    • Amber McPherson · Contactamjackson@usf.edu · +1 813 974 9423
    • John Ciotti · Principal investigator
  • Vero Beach Neurology
    Vero Beach, Florida 32960, United States
    Recruiting
  • Rush University Medical Center
    Chicago, Illinois 60607, United States
    Recruiting
  • University of Chicago
    Chicago, Illinois 60637, United States
    Recruiting
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
    Recruiting
    • Vonda Whitley · Contactvwhitley@kumc.edu · +1 913 588 9600
    • Sharon Lynch · Principal investigator
  • MedStar Montgomery Medical Center
    Olney, Maryland 20832, United States
    Recruiting
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Lahey Hospital and Medical Center
    Burlington, Massachusetts 01805, United States
    Recruiting
    • Anish Panda · ContactAnish.Panda@lahey.org · +1 781 744 3874
    • Dan Michael Pineda · Principal investigator
  • Neurology Center of New England PC
    Foxborough, Massachusetts 02035, United States
    Recruiting
  • Michigan Institute of Neurological
    Farmington Hills, Michigan 48334, United States
    Recruiting
  • Memorial HC Ins for Neuroscience
    Owosso, Michigan 48867, United States
    Recruiting
  • WA Uni School Of Med
    St Louis, Missouri 63110, United States
    Recruiting
    • Kiontay Watson · Contactk.watson@wustl.edu · +1 314 362 3293
    • Matthew R Brier · Principal investigator
  • Cleveland Clinic Foundation
    Las Vegas, Nevada 89106, United States
    Recruiting
    • Laurinda Keelen · Contactkeelenl@ccf.org · +1 702 483 6003
    • Carrie M Hersh · Principal investigator
  • Holy Name Medical Center
    Teaneck, New Jersey 07666, United States
    Recruiting
  • University of New Mexico
    Albuquerque, New Mexico 87131-0001, United States
    Recruiting
    • Emily Reese · Contactejreese@salud.unm.edu · +1 505 272 2836
    • Clotilde Hainline · Principal investigator
  • SUNY Buffalo The Jacobs Neuro Inst
    Buffalo, New York 14203, United States
    Recruiting
  • University of North Carolina
    Chapel Hill, North Carolina 27517, United States
    Recruiting
  • Velocity Clinical Research
    Raleigh, North Carolina 27607, United States
    Recruiting
  • Sanford Health
    Fargo, North Dakota 58102, United States
    Recruiting
  • Premier Health
    Centerville, Ohio 45459, United States
    Recruiting
  • Univ of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
    Recruiting
    • Gideon Gyebi · Contactgyebign@ucmail.uc.edu · + 1 513 558 4489
    • Aram Zabeti · Principal investigator
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    Recruiting
    • Dawn Maniawski · Contactmaniawd@ccf.org · +1 216 445 5788
    • Devon Conway · Principal investigator
  • Ohio Health Research Institute
    Columbus, Ohio 43214, United States
    Recruiting
  • Providence Neurological Services West
    Portland, Oregon 97225, United States
    Recruiting
  • Premier Neurology
    Greenville, South Carolina 29605, United States
    Recruiting
  • Sibyl Wray MD Neurology PC
    Knoxville, Tennessee 37922, United States
    Recruiting
  • Austin Regional Clinic
    Austin, Texas 78731, United States
    Recruiting
  • Univ of Texas Southwest Med Center
    Dallas, Texas 75390-9034, United States
    Recruiting
  • John Peter Smith Hospital
    Fort Worth, Texas 76104, United States
    Recruiting
    • Valentina Jovic · ContactVjovic@jpshealth.org · +1 817 702 1680
    • Horacio Chiong-Rivero · Principal investigator
  • Saturn Research Solutions LLC
    Plano, Texas 75024, United States
    Recruiting
  • Virginia Commonwealth University
    Richmond, Virginia 23298-0111, United States
    Recruiting
  • Center for Neurological Disorders G
    Greenfield, Wisconsin 53228-1321, United States
    Recruiting
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Anna Freiberg · Contactafreiberg@mcw.edu · +1 414 805 5249
    • Ahmed Obeidat · Principal investigator
  • Novartis Investigative Site
    Rosario, Santa Fe Province 2000, Argentina
    Recruiting
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000BZL, Argentina
    Recruiting
  • Novartis Investigative Site
    Buenos Aires, C1055AAF, Argentina
    Recruiting
  • Novartis Investigative Site
    Caba, C1182, Argentina
    Recruiting
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
    Recruiting
  • Novartis Investigative Site
    Liverpool, 2170, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    St Leonards, 2065, Australia
    Recruiting
  • Novartis Investigative Site
    Bruges, 8000, Belgium
    Recruiting
  • Novartis Investigative Site
    Overpelt, 3900, Belgium
    Recruiting
  • Novartis Investigative Site
    Fortaleza, Ceará 60120-002, Brazil
    Recruiting
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90430-001, Brazil
    Recruiting
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90560-032, Brazil
    Recruiting
  • Novartis Investigative Site
    Joinville, Santa Catarina 89202-165, Brazil
    Recruiting
  • Novartis Investigative Site
    São Paulo, São Paulo 01244-030, Brazil
    Recruiting
  • Novartis Investigative Site
    São Paulo, São Paulo 04076-004, Brazil
    Recruiting
  • Novartis Investigative Site
    Edmonton, Alberta T6G 2B7, Canada
    Recruiting
  • Novartis Investigative Site
    Vancouver, British Columbia V6T 2A1, Canada
    Recruiting
  • Novartis Investigative Site
    Lévis, Quebec G6W 0M5, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H4A 3T2, Canada
    Recruiting
  • Novartis Investigative Site
    Brno, 602 00, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Brno, 625 00, Czechia
    Recruiting
  • Novartis Investigative Site
    Hradec Králové, 500 05, Czechia
    Recruiting
  • Novartis Investigative Site
    Jihlava, 586 01, Czechia
    Recruiting
  • Novartis Investigative Site
    Pardubice, 532 03, Czechia
    Recruiting
  • Novartis Investigative Site
    Prague, 150 06, Czechia
    Recruiting
  • Novartis Investigative Site
    Aarhus N, 8200, Denmark
    Recruiting
  • Novartis Investigative Site
    Glostrup Municipality, 2600, Denmark
    Recruiting
  • Novartis Investigative Site
    Bordeaux, 33076, France
    Recruiting
  • Novartis Investigative Site
    Clermont-Ferrand, 63003, France
    Recruiting
  • Novartis Investigative Site
    Lille, 59000, France
    Recruiting
  • Novartis Investigative Site
    Marseille, 13885, France
    Recruiting
  • Novartis Investigative Site
    Nice, 06000, France
    Recruiting
  • Novartis Investigative Site
    Nîmes, 30029, France
    Recruiting
  • Novartis Investigative Site
    Paris, 75940, France
    Recruiting
  • Novartis Investigative Site
    Poitiers, 86021, France
    Recruiting
  • Novartis Investigative Site
    Strasbourg, 67000, France
    Recruiting
  • Novartis Investigative Site
    Toulouse, 31059, France
    Recruiting
  • Novartis Investigative Site
    Tours, 37044, France
    Recruiting
  • Novartis Investigative Site
    Marburg, Hesse 35043, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 13353, Germany
    Recruiting
  • Novartis Investigative Site
    Bochum, 44791, Germany
    Recruiting
  • Novartis Investigative Site
    Erbach im Odenwald, 64711, Germany
    Recruiting
  • Novartis Investigative Site
    Essen, 45147, Germany
    Recruiting
  • Novartis Investigative Site
    Greifswald, 17475, Germany
    Recruiting
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
    Recruiting
  • Novartis Investigative Site
    Münster, 48149, Germany
    Recruiting
  • Novartis Investigative Site
    Ulm, 89073, Germany
    Recruiting
  • Novartis Investigative Site
    Ulm, 89081, Germany
    Recruiting
  • Novartis Investigative Site
    Chaïdári, 124 62, Greece
    Recruiting
  • Novartis Investigative Site
    Larissa, 411 10, Greece
    Recruiting
  • Novartis Investigative Site
    Thessaloniki, 532 46, Greece
    Recruiting
  • Novartis Investigative Site
    Bergamo, BG 24127, Italy
    Recruiting
  • Novartis Investigative Site
    Foggia, FG 71122, Italy
    Recruiting
  • Novartis Investigative Site
    Genova, GE 16132, Italy
    Recruiting

Showing the first 100 of 131 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2029, 49 months after the start.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 49 months is above that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Feb 26, 2025
StartActual
Jun 23, 2025
Primary completionEst.
Jul 25, 2029
CompletionEst.
Jun 25, 2031
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (1 United States, 1 Germany)
  • University of North Carolina · Chapel Hill, United States
  • Novartis Investigative Site · Marburg, Germany
Oct 26, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • Neurology Associates PA · Maitland, United StatesContact a•••@naparesearch.com · •••5996→n•••@gmail.com · •••5996
  • Neurology Center of New England PC · Foxborough, United StatesContact b•••@neurocenterne.com · •••5812→j•••@neurocenterne.com · •••5812
  • Sanford Health · Fargo, United StatesContact d•••@sanfordhealth.org→c•••@sanfordhealth.org · •••2474
  • Premier Neurology · Greenville, United StatesContact j•••@premier-neuro.com · •••4005→a•••@premier-neuro.com · •••4005
  • John Peter Smith Hospital · Fort Worth, United StatesContact none listed→•••1680
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    2 sites added
    Show 2 added (1 United States, 1 Germany)
    • University of North Carolina · Chapel Hill, United States
    • Novartis Investigative Site · Marburg, Germany
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Neurology Associates PA · Maitland, United StatesContact a•••@naparesearch.com · •••5996→n•••@gmail.com · •••5996
    • Neurology Center of New England PC · Foxborough, United StatesContact b•••@neurocenterne.com · •••5812→j•••@neurocenterne.com · •••5812
    • Sanford Health · Fargo, United StatesContact d•••@sanfordhealth.org→c•••@sanfordhealth.org · •••2474
    • Premier Neurology · Greenville, United StatesContact j•••@premier-neuro.com · •••4005→a•••@premier-neuro.com · •••4005
    • John Peter Smith Hospital · Fort Worth, United StatesContact none listed→•••1680
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06846281
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Jun 23, 2025
Primary completion
Jul 25, 2029 (estimated)
Completion
Jun 25, 2031 (estimated)
Last update
Oct 26, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion